BofA analyst Tazeen Ahmad raised the firm’s price target on Neurocrine (NBIX) to $182 from $172 and keeps a Buy rating on the shares. The firm updated its DCF-based model for finalized Crenessity U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback